Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36795415/
This study found that CDK4/6 inhibitors rapidly reached many eligible patients with metastatic breast cancer and were adopted gradually over time in the Netherlands. Adoption of innovative medicines may be...
Conclusions: Findings of the study suggest that, although CDK4/6 inhibitors rapidly reached many patients who were eligible for these treatments, the speed of adoption of innovative medicines may be further optimized and better transparency of the availability of these medicines is needed.
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36765765/
The 1983 discovery of a mouse monoclonal antibody-the Ki-67 antibody-that recognized a nuclear antigen present only in proliferating cells represented a seminal discovery for the pathologic assessment of cellular proliferation...
Conclusions: The goals of this review are to highlight the historical evolution of Ki-67 in breast cancer, summarize the present literature on Ki-67 in breast cancer, and discuss the evolving literature on the use of Ki-67 as a companion diagnostic biomarker in breast cancer, with consideration for the necessary changes required across pathology...
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36756142/
Abemaciclib with ET demonstrated clinically meaningful treatment benefit for IDFS and DRFS versus ET alone regardless of menopausal status and first ET, with a numerically greater benefit in the premenopausal...
Conclusions: Abemaciclib with ET demonstrated clinically meaningful treatment benefit for IDFS and DRFS versus ET alone regardless of menopausal status and first ET, with a numerically greater benefit in the premenopausal compared to the postmenopausal population. Safety data in premenopausal patients are consistent with the overall safety...
-
Breast Cancer Connect3yrKey Points • Source: Therapeutic Advances in Clinical Oncology • Conclusion: “Abemaciclib with ET demonstrated clinically meaningful treatment benefit for IDFS [invasive disease-free survival] and DRFS [distant relapse-free survival] versus ET alone regardless Show More
Piperazine ring toxicity in three novel anti-breast cancer drugs: an in silico and in vitro metabolic bioactivation approach using olaparib as a case study - Naunyn-Schmiedeberg's Archives of Pharmacology
Source : https://link.springer.com/article/10.1007/s00210-023-02413-9
The metabolic activation of small-molecule drugs into electrophilic reactive metabolites is widely recognized as an indicator of idiosyncratic adverse drug reactions (IADRs). Three novel anti-breast cancer drugs containing piperazine rings,...
Conclusions: Three novel anti-breast cancer drugs containing piperazine rings, ribociclib (Kisqali®, RCB), abemaciclib (Verzenio®, ABC), and olaparib (Lynparza®, OLP), were selected to study the effect of different chemical environment on the piperazine ring activation using in silico and in vitro metabolic experiments
Communication Training Helps to Reduce Burnout During COVID-19 Pandemic - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36756035/
Our study found communication training was effective in reducing burnout in healthcare providers, in the setting of the COVID-19 pandemic. The participants felt the communication tools learned from the training...
Conclusions: Our study found communication training was effective in reducing burnout in healthcare providers, in the setting of the COVID-19 pandemic. The participants felt the communication tools learned from the training modules were useful in improving work satisfaction and communication with patients during the pandemic.